Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Protein tyrosine phosphatase 1B (PTP1B) removes phosphate groups from phosphorylated tyrosine proteins in human cells, particularly in the insulin and leptin signaling pathways. It is a key drug target for ailments such as type 2 diabetes and obesity. However, there is a lack of highly specific PTP1B inhibitor drugs. This study employed recombinant that co-expressed PTP1B and v-Src (viral sarcoma protein tyrosine kinase) to screen for novel PTP1B inhibitors derived from actinomycete extracts. Eight extracts significantly suppressed the growth of the recombinant by inhibiting PTP1B expression, indicating their potential as PTP1B inhibitors. In a protein-chip assay, actinomycete extract 4585DW showed PTP1B inhibitory activity comparable to the positive controls, suramin and vanadate. The extract was non-cytotoxic in mammalian and yeast cells and inhibited PTP1B with m and max values of 10.91 ± 0.50 mM and 0.02 ± 0.00 μmol/min, respectively. In conclusion, 4585DW is a promising candidate for further investigation as a PTP1B inhibitor.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283259PMC
http://dx.doi.org/10.4014/jmb.2502.02001DOI Listing

Publication Analysis

Top Keywords

protein tyrosine
12
ptp1b
9
tyrosine phosphatase
8
actinomycete extracts
8
ptp1b inhibitor
8
ptp1b inhibitors
8
screening protein
4
tyrosine
4
phosphatase inhibitors
4
inhibitors actinomycete
4

Similar Publications

[Research status and future direction of irreversible EGFR-TKI in non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of nursing, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are important treatments for EGFR mutant non-small cell lung cancer (NSCLC). However, the first and second generation EGFR-TKI face clinical limitations due to acquired resistance, such as the T790M mutation. Irreversible EGFR-TKI can significantly prolong the survival of patients by enhancing the inhibition of drug-resistant mutations through the covalent binding mechanism.

View Article and Find Full Text PDF

Molecular basis for regulation of the class I phosphoinositide 3-kinases (PI3Ks), and their targeting in human disease.

Biochim Biophys Acta Mol Cell Biol Lipids

September 2025

Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, V8W 2Y2, Canada; University of Victoria Genome BC Proteomics Centre, Vi

The class I phosphoinositide 3-kinase pathway (PI3K) is a master regulator of cellular growth, and plays essential roles in controlling immune cell function, metabolism, chemotaxis and proliferation. Activation of class I PI3Ks generates the signalling lipid PIP that activates multiple pro-growth signalling pathways. Class I PI3Ks can be activated by multiple plasma membrane stimuli, including G-protein coupled receptors, Ras superfamily GTPases, and receptor tyrosine kinases.

View Article and Find Full Text PDF

The myristoylated preS1 domain (myr-preS1) of the hepatitis B virus (HBV) large surface protein is essential for binding to the receptor protein, Na/taurocholate co-transporting polypeptide (NTCP), and for the subsequent internalization of the virus-receptor complex. NTCP, which is expressed in hepatocytes, plays a physiological role in hepatic bile acid transport. Recent cryo-electron microscopy structures of the myr-preS1-NTCP complex were used to analyze virus-receptor interactions at the molecular level.

View Article and Find Full Text PDF

Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.

Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.

View Article and Find Full Text PDF

The present investigation elucidates the therapeutic potential of glycyrrhizin, the predominant triterpene saponin isolated from (licorice), in the management of systemic lupus erythematosus (SLE), an autoimmune disorder characterized by multisystemic involvement and therapeutic recalcitrance. Comprehensive interrogation of multiple disease-specific databases facilitated the identification of crucial SLE-associated molecular targets and hub genes, with MAPK1, MAPK3, TP53, JUN, and JAK2 demonstrating the highest degree of network centrality. Subsequent molecular docking simulations and binding affinity assessments revealed compounds with exceptional complementarity to these pivotal molecular targets, establishing as a pharmacologically promising botanical source and glycyrrhizin as its principal bioactive constituent meriting comprehensive mechanistic investigation.

View Article and Find Full Text PDF